No muscle atrophy without GSK-3␤. Focus on "Glycogen synthase kinase-3␤ is required for the induction of skeletal muscle atrophy" SKELETAL MUSCLE ATROPHY is driven by an imbalance of protein synthesis and degradation, generally in favor of the latter. The ubiquitin-proteasome system (UPS) is commonly regarded as the major proteolytic system involved in breakdown of muscle protein under atrophy-inducing conditions (6) , and the E3 ubiquitin ligases muscle atrophy F-box (MAFbx; also called atrogin-1) and muscle RING finger-1 (MuRF1) are considered the rate-limiting enzymes for the UPS (2, 7). The levels of MAFbx and MuRF1 have been described to be controlled by the insulin-like growth factor (IGF)-I/Akt/Forkhead Box O (FoXO) pathway in which phosphorylation and activation of Akt leads to phosphorylation and retention in the cytoplasm of FoXO transcription factors, thereby decreasing gene expression and subsequent protein abundance of MAFbx and MuRF-1 ( Fig. 1 ) and attenuating muscle proteolysis (6, 9) . In the paper by Verhees et al. (12) , the authors show that the second arm of the IGF-I/Akt pathway, through GSK-3␤, is crucial for the elevation of MAFbx and MuRF-1 and the subsequent decrease in muscle size under atrophy-inducing conditions. In addition, they show for the first time that blocking the GSK-3␤ pathway specifically spares myofibrillar proteins.
Using two in vitro models for muscle atrophy, dexamethasone treatment or inhibition of IGF-I signaling through the application of LY294002 (Fig. 1) , Verhees et al. show an induction of MAFbx and MuRF-1 and a concurrent loss of the myofibrillar proteins myosin heavy chain fast (MyHC-f) and myosin light chains (MLC) 1 and -3. These changes are prevented by the presence of small interfering RNA (siRNA) to GSK-3␤, which produces a loss of the GSK-3␤ protein. Previous studies had shown that inhibition of GSK-3␤ through pharmacological means (4, 5, 13) or use of a dominant negative form of GSK-3␤ (10) prevented muscle atrophy and attenuated muscle protein degradation, but only one study also showed an effect of GSK-3␤ inhibition on MAFbx and MuRF-1 abundance (4). Interestingly, Verhees et al. show that pharmacological versus genetic inhibition of GSK-3␤ has a differential effect on MAFbx compared with MuRF-1, so that the absence of GSK-3␤ protein is associated with a decrease in MAFbx and MuRF-1 mRNA expression while only MAFbx is decreased when GSK-3␤ activity is inhibited through pharmacological means. Therefore, this study shows that the presence of GSK-3␤ protein is required for the induction of MAFbx and MuRF-1 and the subsequent loss of myofibrillar protein (Fig. 1,  dashed arrow) .
Indeed, Verhees et al. show that the attenuation of the loss of protein in response to GSK-3␤ inhibition is specific for myofibrillar protein. With the induction of atrophy, the myofibrillar proteins MyHC-f, MLC-1, and MLC-3 were significantly decreased and these decreases could be rescued by the genetic ablation of GSK-3␤. However, the decrease in GAPDH under the same circumstances was not attenuated by the absence of GSK-3␤ protein, and therefore the authors conclude that the inhibition of the GSK-3␤ pathway is specific for protection of myofibrillar protein. What remains to be determined is which The authors suggest that the potential cross talk between GSK-3␤ and FoXO transcription factors should be investigated, because of their involvement in catabolism (11) . However, the involvement of ␤-catenin should also be considered because this protein is a direct target for phosphorylation by GSK-3␤ (3, 8) , acts as a coactivator for a subset of transcription factors (8) , and is involved in the regulation of skeletal muscle size (1).
In conclusion, the paper by Verhees et al. (12) is an important contribution to our understanding of the pathways involved in muscle atrophy and provides a starting point for potential therapeutic interventions to combat muscle wasting under different pathological and physiological circumstances.
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